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Evaluation of the changes on hemostatic parameters induced by valdecoxib in
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The effects of the cyclooxygenase (COX)-2 selective inhibitor, valdecoxib, on blood
coagulation parameters were evaluated, along with aspirin in male Wistar rats. Groups
of animals were administered a daily oral dose of 10 mg/kg rat of valdecoxib, 100
mg/kg rat of aspirin and the vehicle alone during 4 weeks. Blood samples were collected
at the end of 1, 2, 3 and 4 weeks of administration period and the plasma concentrations
of valdecoxib were determined by RP-HPLC giving mean values of 101.1, 113.5,
164.0 and 184.6 ng/mL, respectively. The same plasma samples were used for the
analysis of hematological parameters and the results compared to the controls.
Valdecoxib induced significant activated partial thromboplastin time reduction (18%)
after 2 weeks and prothrombin time reduction (12.2%) after 3 weeks (P<0.05). There
were no significant changes in the platelet count and fibrinogen levels. The anti-
factor Xa and anti-factor IIa activities showed slight reductions, but only significant
for the anti-factor Xa on the 3rd week (6.7%). The results showed that valdecoxib at
the dose tested with the plasmatic concentrations induced some changes in the
hemostatic function of rats, which can be helpful to understand the side effects and
the safe use of the drug. Rev. bras. hematol. hemoter. 2006;28(1):28-32.
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Introduction
Hemostasis involves a complex system of factors that
work within a delicate balance allowing the body to control
the loss of blood while protecting against tissue ischemia,
necrosis and resultant myocardial infarctions due to blood
clotting in a vessel.1
Cyclooxygenase-2 selective inhibitors have been
marketed since 1999 as alternatives to traditional
nonsteroidal anti-inflammatory drugs (NSAIDs). The COX
enzyme exists in two isoforms, a constitutive isoform
(COX-1) mainly associated with homeostasis, and an
inducible isoform (COX-2) which is associated with
inflammation and is selectively inhibited by the NSAID
valdecoxib, described chemically as 4-(5-methyl-3-
phenylisoxazol-4-yl) benzenesulfonamide.2,3
The expression of COX-2 in the vascular endothelium
has been suggested to explain why the use of a high dose
and chronic administration of valdecoxib has been in some,
but not all studies, associated with increased risk for cardiac
events. The current hypothesis is that while selective COX-
2 inhibition does not affect the proaggregatory and
vasoconstricting effect of thromboxane A2 (TXA2) produced
by thrombocytes, it may significantly block the COX-2
dependent production of endothelial prostacyclin (PGI2)
resulting in an imbalance of the aggregatory system in fa-
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vor of thrombus formation and vasoconstriction.4-7 This ba-
lance of TXA2/PGI2 is crucial to maintain hemostasis of
coagulation pathways that can be evaluated by the clinical
laboratory assays.
Moreover, due to the recent findings, safety monitoring
and additional studies will be essential to understand the
mechanisms and evaluate safe dosage levels of coxibs as
anti-inflammatory and also as a potential new candidate in
the prevention and treatment of cancer.8,9
The aim of the present study was to determine the
plasma concentration achieved by oral administration of a
selected dose of valdecoxib, investigate the effects on
different blood coagulation parameters during the
administration time of four weeks, and compare the results
to those obtained by using aspirin.
Materials and Methods
Materials
The valdecoxib reference standard was generously
supplied by Pfizer Laboratories (Kalamazoo, USA).
Valdecoxib active pharmaceutical ingredient was obtained
from Ultratech India Ltd (New Bombay, India). Aspirin was
purchased from Sigma (St. Louis, USA). Ezetimibe (internal
standard, I.S.) was obtained from Sequoia Research products
(Oxford, United Kingdom). Factor Xa from bovine plasma
was purchased as "DIAGEN" from Diagnostic Reagents Ltd
(Thame, UK) and factor IIa from human plasma was
purchased from Sigma (St. Louis, USA). Chromogenic
substrates S-2765 and S-2238 were from Chromogenix
(Milan, Italy). All other chemicals and reagents used were
of the highest purity and were purchased from Tedia
(Fairfield, USA) and Merck (Darmstadt, Germany).
Animals and test samples
Experimental animal studies were conducted in
accordance with the national protection laws on animal
welfare. Male wistar rats were housed under controlled
conditions. Room temperature was kept constant (20-22 ºC)
with 12:12 h, light-dark cycles and food and water ad libitum
during the trial. A total of seventy-two animals were
distributed in a fully randomized order and divided by color
code into valdecoxib, aspirin and control groups with usually
six rats for each treatment group. The assays were carried
out with animals with a body weight that ranged from 180
to 200 g. Valdecoxib and aspirin were administered once a
day orally by gavage (10 mg/kg and 100 mg/kg, respectively)
as a suspension in 0.5% aqueous carboxymethylcellulose
and control animals received the vehicle.
Methods
Blood collection
The blood collection was carried out on the 1st, 2nd,
3rd, and 4th weeks following continuous daily oral
administration of the respective doses. After anesthetizing
the rats intraperitoneally with sodium pentobarbitone
(40 mg/kg), approximately 5.5 mL of blood was collected
from the abdominal aorta using disposable polypropylene
syringes and 0.5 mL was transferred to a disposable tube
containing 0.05 mL of EDTA, for platelet count. The
remaining blood was immediately transferred to a plastic
tube containing 3.8% sodium citrate solution to give the
anticoagulant-blood ratio 1:10. The blood was mixed gently
and centrifuged at 900×g for 15 minutes at 4ºC. This citrated
plasma was used for the determination of valdecoxib
concentration and coagulation studies (prothrombin time -
PT, activated partial thromboplastin time - APTT, fibrinogen
level and anti-factor Xa and anti-factor IIa activities).
Platelet counting
The platelet counting was performed by the
fluorescence method using an automated flow cytometer
(ABX Diagnostics, Montpellier, France).
Coagulation parameters
The coagulation tests, prothrombin time (PT) and
fibrinogen level were measured in duplicate by the
photometric method using an automated coagulation
analyzer (Sysmex, Kobe, Japan). The activated partial
thromboplastin time (APTT) assay was performed in
triplicate. A total of 100 µL of sodium chloride solution
(9 g/L) and 100 µL of thawed plasma sample was transferred
to respective tubes in the coagulometer at 37 ºC, and allowed
to equilibrate for 5 minutes. Then, 100 µL of a mixture of
equal volumes of kaolin (4 µg/mL) and phospholipid (49.4
µg/mL) was added. After exactly two minutes, 100 µL of
calcium chloride solution (25 mmol/L) was added and the
clotting time recorded for each tube.10
Anti-factor Xa and anti-factor IIa assays
The assays were carried out in triplicate by the method
described with small modifications.11 For anti-factor Xa
assay, a total of 25 µL of plasma was transferred to a well of
a 96-well plate and then allowed to equilibrate at 37°C (water
bath or heating block) before adding 50 µL of bovine factor
Xa solution. The plate was incubated for exactly two min
and then 100 µL of chromogenic substrate S-2765 was added.
The reaction was stopped after exactly four min by adding
100 µL of 20% acetic acid. The absorbance was measured
at 405 nm in a microplate reader. The assay was performed
in triplicate.
Anti-factor IIa assay was carried out changing the
procedure described above for the anti-factor Xa assay by
using bovine factor IIa solution and the chromogenic
substrate S-2238.
Determination of valdecoxib concentration
An isocratic high-performance liquid chromatography
30
Rev. bras. hematol. hemoter. 2006;28(1):28-32                                                                                                                Fronza M et al
procedure was used for quantitative estimation of valdecoxib
in plasma. Valdecoxib and ezetimibe (internal standard) were
extracted from plasma by liquid-liquid extraction using tert-
butil methyl ether extraction solvent and carried out on a
reversed phase Phenomenex (Torrance, USA) Synergi fusion
C18 column (150 mm x 4.6 mm I.D., with a particle size of
4 µm and pore size of 80 Å). A security guard holder (4.0
mm x 3.0 mm I.D.) was used to protect the analytical column.
The HPLC system was operated isocratically and the column
was operated at 40ºC using a mobile phase of water, pH 7.0
adjusted with NaOH 0.1M/acetonitrile (51:49, v/v). This
was filtered through a 0.45 µm membrane filter (Millipore)
and run at a flow rate of 1.0 mL/min and with UV detection
at 210 nm.
Statistical analysis
Data are expressed as means ± S.E.M. Significant
differences between the test and control groups were
determined by the student's t-test, at a level of P <
0.05. (SAS 6.1 for Windows, SAS Institute Inc.,
USA).
Results and Discussion
The experiment was carried out using the
doses selected as, approximately, eight times higher
than the human clinical dose (adjusted to the body
weight), for valdecoxib, and three times higher for
aspirin.12,13 The assay design was established for
the evaluations as subacute biological effects during
one month. The blood samples were collected and
the plasma concentrations of valdecoxib measured
by reverse-phase liquid chromatography (RP-HPLC), as
shown in Table 1.
The mean platelet count was 729 ± 94 × 103 and 704
± 81 × 103 mm3 for valdecoxib and aspirin, respectively.
Comparing the results to the controls and also to each other,
non-significant differences were observed at all
administration times, demonstrating that valdecoxib does
not affect this hematological parameter.
The mean of the fibrinogen level was 198 ± 21 and
201 ± 35 mg/dL for valdecoxib and aspirin, respectively.
There was no significant effect of valdecoxib and aspirin on
fibrinogen level at any time of the experiment.
The blood clotting process is complex, involving many
factors found in the plasma and tissues. Substances that affect
the PT are thought to act on the extrinsic pathway factors:
factors V, VII, X, prothrombin and fibrinogen, while those
that affect the APTT act on the components of the intrinsic
pathway, that is, all coagulation factors except factors VII
and XIII.14 The effects of valdecoxib and aspirin on PT are
shown in Table 2. A significant reduction (12.2%) was
observed only with the group that received valdecoxib during
three weeks (P < 0.05). Administration of the same dose for
four weeks caused a PT prolongation (by 3.7%), when
Table 1
RP-HPLC determination of plasma concentrations (ng/mL)
of valdecoxib following daily oral administration
 of 10 mg/kg rat in male rats
Animals
Concentration (ng/mL)
Time (weeks)
0 1 2 3 4
1 nda 110.6 110.2 153.2 183.1
2 nd 87.8 125.1 147.9 190.2
3 nd 105.3 109.8 180.2 175.3
4 nd 95.7 98.3 165.7 160.4
5 nd 108.4 122.6 172.3 210.1
6 nd 98.9 114.7 164.8 188.7
Mean - 101.1 113.5 164.0 184.6
CV (%) - 8.5 8.6 7.3 9.0
a nd, not detected
Table 2
Effect of administration of valdecoxib and aspirin for 1, 2, 3 and 4 weeks on
prothrombin time (PT) of male rats
Animal Group
Prothrombin time in seconds (mean±S.E.M.)*
1 week 2 weeks 3 weeks 4 weeks
Control 11.1 ± 0.07 10.9 ± 0.13 10.6 ± 0.07 10.8 ± 0.35
Aspirin 11.2 ± 0.43 11.1 ± 0.30 11.0 ± 0.45 11.3 ± 0.62
Valdecoxib 11.2 ± 0.31 10.8 ± 0.47 9.3 ± 0.33** 11.2 ± 0.15
* six rats per group
** Student's t-test, significantly different from control P<0.05
compared to that of the control, but the difference was not
statistically significant. The group receiving aspirin showed
prolongation of the PT compared to that of the control,
during all the experiment, although changes were not
significant.
The APTT assay showed that there was a significant
shortening of the APTT results (by 18%) after
administration for two weeks, compared to the controls (P
< 0.05) (Table 3). Aspirin produced an increase of APTT
during all the experiment, but these data were not
statistically significant.
The effects of valdecoxib and aspirin on factor Xa and
factor IIa of the coagulation cascade are shown in Figure 1.
For the anti-factor Xa a reduction of 3.1, 2.2 and 6.7% was
observed after 1, 2 and 3 weeks, respectively, but the
difference was significant only in the 3rd week (P<0.05).
This shortening of anti-Xa activity (units/mL) indicated that
the use of valdecoxib can cause some coagulant effect,
probably due to the decrease of natural inhibitors of
coagulation like antithrombin, protein C, protein S or tissue
factor pathway inhibitor. Furthermore for all the experiment,
aspirin showed an increase of anti-Xa activity of 3.0, 6.5,
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6.3 and 5.9%, compared to the controls, but despite of being
non-significant (P>0.05), it is confirming the known anti-
aggregating effect of the drug.
In parallel, when evaluating the anti-factor IIa activity
of valdecoxib, a slight non-significant reduction was found
calculated at 1.1 and 3.1% for the 1st and 2nd week,
respectively. For the following two weeks there were no
changes. Besides, aspirin showed an increase of the anti-IIa
activity of 3.2, 3.5, 1.9 and 4%, that was non-significant.
Coagulation consists of a series of zymogens that can
be converted by limited proteolysis to active enzymes leading
to the generation of thrombin, which in turn converts
fibrinogen into fibrin. Based on the present evidence,
valdecoxib may be related to the initiation of
coagulation cascade and thrombus formation that
could be helpful to understand cardiovascular
complications, such as myocardial infarction
reported with valdecoxib.4 This idea is supported
by our data showing that significant reduction was
found for APTT, PT and anti-factor Xa.
Conclusion
On the basis of the present findings, using
daily oral administration at a selected dose, eight
times higher than that intended for human
therapeutic use, during one-month, valdecoxib seems to
produce some changes in the blood coagulation parameters,
with emphasis on APTT, PT and factor Xa. The results are
important to understand the side effects and for the safe
use of valdecoxib for inflammatory diseases or the
prevention and treatment of cancer, leading to comparisons
of more established drugs of the respective pharmacological
group.
Resumo
Avaliaram-se os efeitos do valdecoxibe, um inibidor seletivo da
cicloxigenase-2 (COX-2), sobre os parâmetros sangüíneos da co-
agulação em ratos Wistar utilizando-se paralelamente a aspiri-
na. Os animais foram divididos em grupos e submetidos à admi-
nistração oral diária de 10 mg/kg animal para o valdecoxib, 100
mg/kg animal para a aspirina e veículo para o grupo controle,
durante quatro semanas. A coleta do sangue foi efetuada após
uma, duas, três e quatro semanas, e as concentrações plasmáticas
do valdecoxibe determinadas por cromatografia líquida, obten-
do-se valores médios de 101,1 - 113,5 - 164 e 184,6 ng/ml, res-
pectivamente. As amostras de plasma foram também usadas para
as análises hematológicas e os resultados comparados aos dos
controles. O valdecoxibe apresentou redução significativa no
TTPA (18%) após duas semanas, e redução do TP (12,2%) após
três semanas (P<0.05). Os efeitos observados na contagem de
plaquetas e nos níveis plasmáticos de fibrinogênio não foram
significativos. As atividades anti-fator Xa e anti-fator IIa apre-
sentaram redução, porém os resultados foram significativos so-
mente para o anti-fator Xa na terceira semana (6,7%). Os resul-
tados experimentais com as concentrações plasmáticas alcan-
çadas demonstram que o valdecoxibe pode induzir alterações
nos parâmetros hematológicos dos ratos. Esses dados poderão
contribuir para a melhor compreensão dos efeitos colaterais e
uso do fármaco com segurança. Rev. bras. hematol. hemoter.
2006;28(1):28-32.
Palavras-chave: Valdecoxibe; coagulação; cromatografia líqui-
da; ratos; fator Xa.
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Table 3
Effect of administration of valdecoxib and aspirin for 1, 2, 3 and 4 weeks on
activated partial thromboplastin time (APTT) of male rats
Animal Group
Activated partial thromboplastin time,
in seconds (mean±S.E.M.)*
1 week 2 weeks 3 weeks 4 weeks
Control 39.2 ± 1.61 41.5 ± 1.30 41.3 ± 1.15 44.3 ± 1.17
Aspirin 39.4 ± 0.90 44.3 ± 1.26 42.3 ± 0.71 48.1 ± 1.51
Valdecoxib 38.2 ± 0.58 34.0 ± 0.62** 39.9 ± 0.85 48.2 ± 1.18
* Six rats/group
** Student's t-test, significantly different from controls P<0.05
Figure 1.  Anti-factor Xa activity (A) and anti-factor IIa activity (B)
evaluated in plasma after daily oral administration of 10 mg/kg rat of
valdecoxib and 100 mg/kg rat of aspirin, respectively,  at 1, 2, 3 and 4
weeks. Groups of six rats and the data expressed as mean ± S.D
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